|
WO2005019255A1
(en)
*
|
2003-08-25 |
2005-03-03 |
Pieris Proteolab Ag |
Muteins of tear lipocalin
|
|
EP2899277A1
(de)
|
2004-11-26 |
2015-07-29 |
Pieris AG |
Verbindung mit Affinität für das zytotoxische T-Lymphozyten-assoziierte Antigen (CTLA-4)
|
|
US7611847B2
(en)
|
2005-06-01 |
2009-11-03 |
Agency For Science, Technology And Research |
Method for identifying an intestinal phenotype
|
|
EP1989529A4
(de)
|
2006-02-13 |
2010-09-01 |
Agency Science Tech & Res |
Verfahren zur bearbeitung einer biologischen und/oder chemischen probe
|
|
JP4987885B2
(ja)
|
2006-03-09 |
2012-07-25 |
エージェンシー フォー サイエンス，テクノロジー アンド リサーチ |
小滴中で反応を行うための装置及びその使用方法
|
|
US8598317B2
(en)
|
2006-03-20 |
2013-12-03 |
Technische Universitaet Muenchen |
Muteins of tear lipocalin with affinity for the T-cell coreceptor CD4
|
|
CN101516907B
(zh)
*
|
2006-08-01 |
2015-08-26 |
皮里斯股份公司 |
泪液脂质运载蛋白的突变蛋白及其获得方法
|
|
SG173332A1
(en)
|
2006-08-01 |
2011-08-29 |
Pieris Ag |
Muteins of tear lipocalin and methods for obtaining the same
|
|
US9874501B2
(en)
|
2006-11-24 |
2018-01-23 |
Curiox Biosystems Pte Ltd. |
Use of chemically patterned substrate for liquid handling, chemical and biological reactions
|
|
WO2008063135A1
(en)
|
2006-11-24 |
2008-05-29 |
Agency For Science, Technology And Research |
Apparatus for processing a sample in a liquid droplet and method of using the same
|
|
JP2010523652A
(ja)
|
2007-04-13 |
2010-07-15 |
エージェンシー フォー サイエンス，テクノロジー アンド リサーチ |
腫瘍発生を制御する方法および腫瘍発生のリスクを診断する方法
|
|
SG185942A1
(en)
|
2007-11-02 |
2012-12-28 |
Agency Science Tech & Res |
Methods and compounds for preventing and treating a tumour
|
|
WO2013114217A1
(en)
|
2012-02-05 |
2013-08-08 |
Curiox Biosystems Pte Ltd. |
Array plates and methods for making and using same
|
|
US10725020B2
(en)
|
2007-11-14 |
2020-07-28 |
Curiox Biosystems Pte Ltd. |
High throughput miniaturized assay system and methods
|
|
EP2222709B1
(de)
|
2007-11-30 |
2016-11-23 |
Glaxo Group Limited |
Antigenbindende konstrukte
|
|
CN106986926A
(zh)
*
|
2008-01-30 |
2017-07-28 |
皮里斯股份公司 |
具有对人c‑met受体酪氨酸激酶的亲和性的泪脂质运载蛋白的突变蛋白及其获得方法
|
|
US20090274623A1
(en)
*
|
2008-01-30 |
2009-11-05 |
General Electric Company |
In vivo imaging agents for met receptor tyrosine kinase
|
|
WO2009132351A2
(en)
*
|
2008-04-25 |
2009-10-29 |
University Of Medicine And Dentistry Of New Jersey |
Anti-sense microrna expression vectors
|
|
JP2011522520A
(ja)
|
2008-05-06 |
2011-08-04 |
エージェンシー フォー サイエンス，テクノロジー アンド リサーチ |
細胞の脱分化を行う方法
|
|
UY31807A
(es)
|
2008-05-06 |
2009-12-14 |
Glaxo Group Ltd |
Encapsulación de agentes biológicamente activos
|
|
EP3381933B1
(de)
|
2008-06-24 |
2020-06-03 |
Technische Universität München |
Muteine von hngal und verwandte proteine mit affinität für ein gegebenes target
|
|
JP2010074915A
(ja)
*
|
2008-09-17 |
2010-04-02 |
Jtekt Corp |
モータ制御装置及び電動パワーステアリング装置
|
|
US8716420B2
(en)
|
2008-10-13 |
2014-05-06 |
Agency For Science, Technology And Research |
Amphiphilic polymers and nanocrystals coated therewith
|
|
EP2189539B2
(de)
|
2008-11-21 |
2018-06-13 |
Chimera Biotec GmbH |
Konjugatkomplexe zum Analytnachweis
|
|
AR074777A1
(es)
|
2008-12-19 |
2011-02-09 |
Glaxo Group Ltd |
Proteinas de union a antigeno
|
|
CA2753263A1
(en)
|
2009-02-24 |
2010-09-02 |
Glaxo Group Limited |
Multivalent and/or multispecific rankl-binding constructs
|
|
US20110305692A1
(en)
|
2009-02-24 |
2011-12-15 |
Glaxo Group Limited |
Antigen-binding contructs
|
|
EP2401297A1
(de)
|
2009-02-24 |
2012-01-04 |
Glaxo Group Limited |
Antigenbindende konstrukte
|
|
US8784752B2
(en)
|
2009-04-17 |
2014-07-22 |
Curiox Biosystems Pte Ltd |
Use of chemically patterned substrate for liquid handling, chemical and biological reactions
|
|
SG177395A1
(en)
|
2009-07-07 |
2012-02-28 |
Agency Science Tech & Res |
Methods of identifying a pair of binding partners
|
|
JP5426026B2
(ja)
|
2009-07-28 |
2014-02-26 |
エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト |
非侵襲性インビボ光学イメージング方法
|
|
AU2010280688A1
(en)
*
|
2009-08-05 |
2012-02-23 |
Allergan, Inc. |
Controlled release formulations of lipocalin muteins
|
|
EP2510357B1
(de)
|
2009-12-07 |
2016-03-30 |
Pieris AG |
Muteine von humanem lipocalin 2 (lcn2, hngal) mit affinität für ein bestimmtes zielmolekül
|
|
EP2516995B1
(de)
|
2009-12-22 |
2016-10-26 |
Agency For Science, Technology And Research |
Nachweis von analyten auf sers-basis
|
|
KR20130028055A
(ko)
|
2010-01-28 |
2013-03-18 |
글락소 그룹 리미티드 |
Ｃｄ １２７ 결합 단백질
|
|
KR101341640B1
(ko)
*
|
2010-02-05 |
2013-12-16 |
한국전자통신연구원 |
단백질 미세 구조 분석 방법 및 단백질 미세 구조 분석용 어레이
|
|
MX342017B
(es)
|
2010-03-26 |
2016-09-09 |
Dartmouth College |
Proteina mediadora de celula t regulatoria vista, agentes de enlace de vista y uso de los mismos.
|
|
US20150231215A1
(en)
|
2012-06-22 |
2015-08-20 |
Randolph J. Noelle |
VISTA Antagonist and Methods of Use
|
|
US10745467B2
(en)
|
2010-03-26 |
2020-08-18 |
The Trustees Of Dartmouth College |
VISTA-Ig for treatment of autoimmune, allergic and inflammatory disorders
|
|
CN102939538A
(zh)
|
2010-05-07 |
2013-02-20 |
霍夫曼-拉罗奇有限公司 |
用于离体检测细胞的诊断方法
|
|
AR081556A1
(es)
|
2010-06-03 |
2012-10-03 |
Glaxo Group Ltd |
Proteinas de union al antigeno humanizadas
|
|
AU2011263786B2
(en)
*
|
2010-06-08 |
2014-11-13 |
Astrazeneca Ab |
Tear lipocalin muteins binding IL-4 R alpha
|
|
WO2012011877A2
(en)
|
2010-07-23 |
2012-01-26 |
Curiox Biosystems Pte Ltd |
Apparatus and method for multiple reactions in small volumes
|
|
CN103154023B
(zh)
|
2010-08-16 |
2017-04-05 |
皮里斯制药有限公司 |
铁调素的结合蛋白
|
|
WO2012032069A1
(en)
|
2010-09-07 |
2012-03-15 |
Pieris Ag |
Recombinant bacterial lipocalin blc and uses thereof
|
|
MX349622B
(es)
*
|
2010-09-08 |
2017-08-07 |
Halozyme Inc |
Metodos para evaluar e identificar o evolucionar proteinas terapeuticas condicionalmente activas.
|
|
US9260492B2
(en)
|
2010-11-15 |
2016-02-16 |
Pieris Ag |
Muteins of human lipocalin 2 with affinity for glypican-3 (GPC-3)
|
|
EP2643352B1
(de)
|
2010-11-23 |
2018-05-02 |
Glaxo Group Limited |
Antigenbindende proteine zur bindung von oncostatin m (osm)
|
|
SG190362A1
(en)
|
2010-11-24 |
2013-06-28 |
Glaxo Group Ltd |
Multispecific antigen binding proteins targeting hgf
|
|
EP2646552B1
(de)
|
2010-12-02 |
2017-07-05 |
Pieris Pharmaceuticals GmbH |
Muteine von menschlichem lipocalin 2 mit affinität für ctla-4
|
|
WO2012136685A1
(en)
|
2011-04-04 |
2012-10-11 |
Pieris Ag |
Methods and compositions for anti-vegf and anti-c-met therapy
|
|
US9409987B2
(en)
|
2011-04-15 |
2016-08-09 |
Compugen Ltd |
Polypeptides and polynucleotides, and uses thereof for treatment of immune related disorders and cancer
|
|
SI3415531T1
(sl)
|
2011-05-27 |
2023-12-29 |
Glaxo Group Limited |
Bcma (cd269/tnfrsf17) - vezni proteini
|
|
CA2838246C
(en)
|
2011-06-13 |
2018-07-10 |
Csl Limited |
Antibodies against g-csfr and uses thereof
|
|
WO2013048986A1
(en)
|
2011-09-26 |
2013-04-04 |
Knoa Software, Inc. |
Method, system and program product for allocation and/or prioritization of electronic resources
|
|
AU2012327878A1
(en)
|
2011-10-28 |
2014-05-29 |
Patrys Limited |
PAT-LM1 epitopes and methods for using same
|
|
US9610356B2
(en)
|
2011-12-12 |
2017-04-04 |
Pieris Pharmaceutical GmbH |
Methods for preventing or treating disorders by increasing bioavailability of iron and related pharmaceutical formulation
|
|
WO2013087660A1
(en)
|
2011-12-13 |
2013-06-20 |
Pieris Ag |
Methods for preventing or treating certain disorders by inhibiting binding of il-4 and/or il-13 to their respective receptors
|
|
WO2013102144A2
(en)
|
2011-12-30 |
2013-07-04 |
Halozyme, Inc. |
Ph20 polypeptede variants, formulations and uses thereof
|
|
EP2802341B1
(de)
|
2012-01-09 |
2019-03-06 |
Pieris Pharmaceuticals GmbH |
Zusammensetzungen und verfahren zur prävention, behandlung und diagnose von erkrankungen
|
|
US9758554B2
(en)
|
2012-01-31 |
2017-09-12 |
Technische Universitaet Muenchen |
Muteins of α1m lipocalin and method of production therefor
|
|
PT2814843T
(pt)
|
2012-02-13 |
2020-06-18 |
Agency Science Tech & Res |
Anticorpos monoclonais humanos neutralizantes de il-b
|
|
GB2502127A
(en)
|
2012-05-17 |
2013-11-20 |
Kymab Ltd |
Multivalent antibodies and in vivo methods for their production
|
|
US9522940B2
(en)
*
|
2012-05-23 |
2016-12-20 |
Pieris Pharmaceuticals Gmbh |
Lipocalin muteins with binding-affinity for glypican-3 (GPC-3) and use of lipocalin muteins for target-specific delivery to cells expressing GPC-3
|
|
WO2013189521A1
(en)
|
2012-06-19 |
2013-12-27 |
Waclawczyk Simon |
Method of generating cells of hepatocyte phenotype
|
|
US9890215B2
(en)
|
2012-06-22 |
2018-02-13 |
King's College London |
Vista modulators for diagnosis and treatment of cancer
|
|
CN104619722B
(zh)
|
2012-06-22 |
2022-10-04 |
达特茅斯大学理事会 |
新型vista-ig构建体和vista-ig用于治疗自身免疫性、过敏性和炎性疾病的用途
|
|
CA2884704C
(en)
|
2012-09-07 |
2023-04-04 |
Randolph J. Noelle |
Vista modulators for diagnosis and treatment of cancer
|
|
WO2014072306A1
(en)
|
2012-11-08 |
2014-05-15 |
F. Hoffmann-La Roche Ag |
Her3 antigen binding proteins binding to the beta-hairpin of her3
|
|
US10526384B2
(en)
|
2012-11-19 |
2020-01-07 |
Pieris Pharmaceuticals Gmbh |
Interleukin-17A-specific and interleukin-23-specific binding polypeptides and uses thereof
|
|
SG11201505856TA
(en)
|
2013-03-14 |
2015-08-28 |
Daiichi Sankyo Co Ltd |
Novel binding proteins for pcsk9
|
|
TW201534726A
(zh)
|
2013-07-03 |
2015-09-16 |
Halozyme Inc |
熱穩定ｐｈ２０玻尿酸酶變異體及其用途
|
|
US9557318B2
(en)
|
2013-07-09 |
2017-01-31 |
Curiox Biosystems Pte Ltd. |
Array plates for washing samples
|
|
CA2926215A1
(en)
|
2013-10-06 |
2015-04-09 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Modified pseudomonas exotoxin a
|
|
RU2718054C2
(ru)
|
2013-11-28 |
2020-03-30 |
СиЭсЭл ЛИМИТЕД |
Способ лечения нефропатии
|
|
CN105979965B
(zh)
|
2013-12-18 |
2021-07-09 |
杰特有限公司 |
治疗伤口的方法
|
|
EP4043493A1
(de)
|
2013-12-24 |
2022-08-17 |
Janssen Pharmaceutica NV |
Anti-vista-antikörper und -fragmente
|
|
US11014987B2
(en)
|
2013-12-24 |
2021-05-25 |
Janssen Pharmaceutics Nv |
Anti-vista antibodies and fragments, uses thereof, and methods of identifying same
|
|
US10927154B2
(en)
|
2014-01-13 |
2021-02-23 |
Pieris Pharmaceuticals Gmbh |
Multi-specific polypeptide useful for localized tumor immunomodulation
|
|
LU92409B1
(en)
|
2014-03-21 |
2015-09-22 |
Philipps Universit T Marburg |
Means and methods for itaconic acid production
|
|
CA2949405C
(en)
*
|
2014-05-22 |
2023-08-01 |
Pieris Pharmaceuticals Gmbh |
Novel specific-binding polypeptides and uses thereof
|
|
EP3154585B1
(de)
|
2014-06-11 |
2022-02-23 |
Kathy A. Green |
Verwendung von vista-agonisten und antagonisten zur unterdrückung oder verbesserung der humoralen immunität
|
|
WO2016059602A2
(en)
|
2014-10-16 |
2016-04-21 |
Glaxo Group Limited |
Methods of treating cancer and related compositions
|
|
MX391388B
(es)
|
2014-11-14 |
2025-03-21 |
Hoffmann La Roche |
Moléculas de unión a antígeno que comprenden un trímero de ligando de la familia de tnf.
|
|
JP2018505911A
(ja)
|
2014-12-05 |
2018-03-01 |
イミュネクスト，インコーポレーテッド |
推定上のｖｉｓｔａ受容体としてのｖｓｉｇ８の同定と、ｖｉｓｔａ／ｖｓｉｇ８調節剤を産生するためのその使用
|
|
EP3245288A1
(de)
|
2015-01-12 |
2017-11-22 |
Pieris Pharmaceuticals GmbH |
Manipulierte t-zellen und verwendungen davon
|
|
RU2720688C2
(ru)
|
2015-01-28 |
2020-05-12 |
ПИЕРИС ФАРМАСЬЮТИКАЛС ГмбХ |
Новые белки, специфические в отношении ангиогенеза
|
|
EP3064507A1
(de)
|
2015-03-06 |
2016-09-07 |
Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts |
Fusionsproteine mit einem bindenden Protein und einem Interleukin-15-Polypeptid mit reduzierter Affinität für IL15ra und therapeutische Verwendungen davon
|
|
AU2016258977C1
(en)
|
2015-05-04 |
2022-07-14 |
Pieris Pharmaceuticals Gmbh |
Anti-cancer fusion polypeptide
|
|
AU2016258952C1
(en)
*
|
2015-05-04 |
2020-12-24 |
Pieris Pharmaceuticals Gmbh |
Proteins specific for CD137
|
|
RU2754466C2
(ru)
|
2015-05-18 |
2021-09-02 |
ПИЕРИС ФАРМАСЬЮТИКАЛС ГмбХ |
Слитый полипептид с противораковой активностью
|
|
US10273275B2
(en)
|
2015-05-18 |
2019-04-30 |
Pieris Pharmaceuticals Gmbh |
Muteins of human lipocalin 2 with affinity for glypican-3 (GPC3) and methods of use thereof
|
|
US10545139B2
(en)
|
2015-06-16 |
2020-01-28 |
Curiox Biosystems Pte Ltd. |
Methods and devices for performing biological assays using magnetic components
|
|
EP3722314A1
(de)
|
2015-06-24 |
2020-10-14 |
Janssen Pharmaceutica NV |
Anti-vista-antikörper und -fragmente
|
|
EP3115066A1
(de)
|
2015-07-07 |
2017-01-11 |
Technische Universität München |
Neuartige psma-spezifische bindeproteine
|
|
CA2988831A1
(en)
|
2015-07-15 |
2017-01-19 |
Pieris Pharmaceuticals Gmbh |
Novel proteins specific for lag-3
|
|
EP3331901A1
(de)
|
2015-08-07 |
2018-06-13 |
Pieris Pharmaceuticals GmbH |
Neuartiges, für lag-3 und pd-1 spezifisches fusionspolypeptid
|
|
AR106188A1
(es)
|
2015-10-01 |
2017-12-20 |
Hoffmann La Roche |
Anticuerpos anti-cd19 humano humanizados y métodos de utilización
|
|
BR112018002570A2
(pt)
|
2015-10-02 |
2018-10-16 |
Hoffmann La Roche |
molécula de ligação ao antígeno biespecífica, anticorpo biespecífico, polinucleotídeos, anticorpo que se liga especificamente ao ox40, composição farmacêutica e método para inibir o crescimento de células tumorais em um indivíduo
|
|
DK3356411T3
(da)
|
2015-10-02 |
2021-09-06 |
Hoffmann La Roche |
Bispecifikke antistoffer, der er specifikke for PD1 og TIM3
|
|
KR20180054877A
(ko)
|
2015-10-07 |
2018-05-24 |
에프. 호프만-라 로슈 아게 |
공자극 tnf 수용체에 대해 4가를 갖는 이중특이적 항체
|
|
CN108368167B
(zh)
|
2015-11-27 |
2023-09-05 |
杰特有限公司 |
Cd131结合蛋白及其应用
|
|
CN108699162A
(zh)
|
2015-11-30 |
2018-10-23 |
皮里斯澳大利亚有限公司 |
新型抗血管生成融合多肽
|
|
TW201725212A
(zh)
|
2015-12-10 |
2017-07-16 |
第一三共股份有限公司 |
特異性於降鈣素基因相關胜肽的新穎蛋白
|
|
TW202216201A
(zh)
|
2016-02-12 |
2022-05-01 |
比利時商楊森製藥公司 |
抗vista抗體及片段、其用途及鑑定其之方法
|
|
EP3231813A1
(de)
|
2016-03-29 |
2017-10-18 |
F. Hoffmann-La Roche AG |
Trimere kostimulatorische tnf-familien-ligandenhaltige antigenbindende moleküle
|
|
JP7184751B2
(ja)
|
2016-04-15 |
2022-12-06 |
イミュネクスト インコーポレイテッド |
抗ヒトｖｉｓｔａ抗体およびその使用
|
|
WO2017194442A1
(en)
|
2016-05-11 |
2017-11-16 |
F. Hoffmann-La Roche Ag |
Antigen binding molecules comprising a tnf family ligand trimer and a tenascin binding moiety
|
|
EP3243832A1
(de)
|
2016-05-13 |
2017-11-15 |
F. Hoffmann-La Roche AG |
Antigenbindende moleküle mit einem ligandentrimer der tnf-familie und pd1-bindungsteil
|
|
JP2020501508A
(ja)
|
2016-09-15 |
2020-01-23 |
クアドルセプト バイオ リミテッド |
多量体、四量体および八量体
|
|
AU2017331739A1
(en)
|
2016-09-23 |
2019-03-07 |
Csl Limited |
Coagulation factor binding proteins and uses thereof
|
|
WO2018087108A1
(en)
|
2016-11-09 |
2018-05-17 |
Pieris Pharmaceuticals Gmbh |
Proteins specific for cd137
|
|
CN117752798A
(zh)
|
2016-12-19 |
2024-03-26 |
豪夫迈·罗氏有限公司 |
用靶向性4-1bb(cd137)激动剂的组合疗法
|
|
MX2019006954A
(es)
|
2016-12-20 |
2019-08-01 |
Hoffmann La Roche |
Terapia de combinacion de anticuerpos biespecificos anti-cd20/anti-cd3 y agonistas de 4-1bb (cd137).
|
|
KR20190099527A
(ko)
|
2017-01-03 |
2019-08-27 |
에프. 호프만-라 로슈 아게 |
항-4-1bb 클론 20h4.9를 포함하는 이중특이성 항원 결합 분자
|
|
RU2019122482A
(ru)
*
|
2017-01-18 |
2021-02-19 |
Пирис Фармасьютикалс Гмбх |
Мутеины липокалина с аффинностью связывания в отношении lag-3
|
|
WO2018134279A1
(en)
|
2017-01-18 |
2018-07-26 |
Pieris Pharmaceuticals Gmbh |
Novel fusion polypeptides specific for lag-3 and pd-1
|
|
JP7196094B2
(ja)
|
2017-03-29 |
2022-12-26 |
エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト |
共刺激ｔｎｆ受容体のための二重特異性抗原結合分子
|
|
WO2018178074A1
(en)
|
2017-03-29 |
2018-10-04 |
F. Hoffmann-La Roche Ag |
Trimeric antigen binding molecules specific for a costimulatory tnf receptor
|
|
EP3601346A1
(de)
|
2017-03-29 |
2020-02-05 |
H. Hoffnabb-La Roche Ag |
Bispezifische antigenbindemoleküle für einen co-stimulierenden tnf-rezeptor
|
|
TWI704158B
(zh)
|
2017-04-04 |
2020-09-11 |
瑞士商赫孚孟拉羅股份公司 |
能夠特異性結合至cd40及fap之新穎雙特異性抗原結合分子
|
|
SG11201909154SA
(en)
|
2017-04-05 |
2019-10-30 |
Hoffmann La Roche |
Bispecific antibodies specifically binding to pd1 and lag3
|
|
KR20220132668A
(ko)
|
2017-04-05 |
2022-09-30 |
큐리옥스 바이오시스템즈 피티이 엘티디. |
어레이 플레이트 상의 샘플을 세정하기 위한 방법, 디바이스 및 장치
|
|
JP7733443B2
(ja)
|
2017-09-11 |
2025-09-03 |
モナシュ ユニバーシティー |
ヒトトロンビン受容体ｐａｒ４に対する結合タンパク質
|
|
US11466073B2
(en)
|
2017-10-18 |
2022-10-11 |
Csl Limited |
Human serum albumin variants and uses thereof
|
|
EP3703746A1
(de)
|
2017-11-01 |
2020-09-09 |
F. Hoffmann-La Roche AG |
Neuartige antigenbindende moleküle mit ligandentrimer der tnf-familie
|
|
IL272747B2
(en)
|
2017-11-01 |
2025-04-01 |
Hoffmann La Roche |
Bispecific antibodies 1 + 2
|
|
CA3079036A1
(en)
|
2017-11-01 |
2019-05-09 |
F. Hoffmann-La Roche Ag |
Combination therapy with targeted ox40 agonists
|
|
JP7465210B2
(ja)
|
2017-11-29 |
2024-04-10 |
シーエスエル リミティド |
虚血－再灌流障害の治療又は予防方法
|
|
EP3502140A1
(de)
|
2017-12-21 |
2019-06-26 |
F. Hoffmann-La Roche AG |
Kombinationstherapie von tumorabgezielten icos-agonisten mit t-zellenbispezifischen molekülen
|
|
TWI841551B
(zh)
|
2018-03-13 |
2024-05-11 |
瑞士商赫孚孟拉羅股份公司 |
使用靶向4-1bb (cd137)之促效劑的組合療法
|
|
CA3092002A1
(en)
|
2018-03-13 |
2019-09-19 |
F. Hoffmann-La Roche Ag |
Therapeutic combination of 4-1 bb agonists with anti-cd20 antibodies
|
|
US12281160B2
(en)
|
2018-03-23 |
2025-04-22 |
Csl Limited |
Method of treating asthma
|
|
CA3094235A1
(en)
|
2018-04-13 |
2019-10-17 |
F. Hoffmann-La Roche Ag |
Her2-targeting antigen binding molecules comprising 4-1bbl
|
|
EP3810642A1
(de)
|
2018-06-21 |
2021-04-28 |
Technische Universität München |
Hepatitis-b- und/oder hepatitis-d-permissive zellen und tiere
|
|
TW202035447A
(zh)
|
2018-07-04 |
2020-10-01 |
瑞士商赫孚孟拉羅股份公司 |
新穎雙特異性促效性4-1bb抗原結合分子
|
|
LT3830120T
(lt)
|
2018-07-31 |
2023-07-10 |
Pieris Pharmaceuticals Gmbh |
Naujas sulietas baltymas specifinis cd137 ir pd-l1 atžvilgiu
|
|
EP3861025A1
(de)
|
2018-10-01 |
2021-08-11 |
F. Hoffmann-La Roche AG |
Bispezifische antigenbindende moleküle mit dreiwertiger bindung an cd40
|
|
SG11202102477QA
(en)
|
2018-10-01 |
2021-04-29 |
Hoffmann La Roche |
Bispecific antigen binding molecules comprising anti-fap clone 212
|
|
MX2021007320A
(es)
|
2018-12-21 |
2021-07-07 |
Hoffmann La Roche |
Moleculas agonistas de union al antigeno cd28 que actuan sobre el tumor.
|
|
US20200223925A1
(en)
|
2018-12-21 |
2020-07-16 |
Hoffmann-La Roche Inc. |
Tumor-targeted superagonistic cd28 antigen binding molecules
|
|
IL284687B2
(en)
|
2019-02-26 |
2025-11-01 |
Pieris Pharmaceuticals Gmbh |
Novel fusion proteins specific for cd137 and gpc3
|
|
GB201903767D0
(en)
|
2019-03-19 |
2019-05-01 |
Quadrucept Bio Ltd |
Multimers, tetramers & octamers
|
|
CA3133422A1
(en)
|
2019-03-29 |
2020-10-08 |
Astrazeneca Ab |
Lipocalin mutein for treatment of asthma
|
|
US20220168387A1
(en)
|
2019-03-29 |
2022-06-02 |
Pieris Pharmaceuticals Gmbh |
Inhaled administration of lipocalin muteins
|
|
WO2020208049A1
(en)
|
2019-04-12 |
2020-10-15 |
F. Hoffmann-La Roche Ag |
Bispecific antigen binding molecules comprising lipocalin muteins
|
|
CA3141378A1
(en)
|
2019-06-26 |
2020-12-30 |
F. Hoffmann-La Roche Ag |
Fusion of an antibody binding cea and 4-1bbl
|
|
EP3990492A1
(de)
|
2019-06-27 |
2022-05-04 |
F. Hoffmann-La Roche AG |
Neuartige icos-antikörper und tumorspezifische antigenbindende moleküle damit
|
|
WO2021089588A1
(en)
|
2019-11-04 |
2021-05-14 |
Pieris Pharmaceuticals Gmbh |
Her2/4-1bb bispecific fusion proteins for the treatment of cancer
|
|
WO2021190980A1
(en)
|
2020-03-22 |
2021-09-30 |
Quadrucept Bio Limited |
Multimers for viral strain evolution
|
|
AR121706A1
(es)
|
2020-04-01 |
2022-06-29 |
Hoffmann La Roche |
Moléculas de unión a antígeno biespecíficas dirigidas a ox40 y fap
|
|
CN115768475A
(zh)
|
2020-06-04 |
2023-03-07 |
Csl创新私人有限公司 |
治疗或预防急性呼吸窘迫综合征的方法
|
|
CN116249709A
(zh)
|
2020-06-05 |
2023-06-09 |
皮里斯制药有限公司 |
靶向4-1bb的多聚体免疫调节剂
|
|
MX2022015795A
(es)
|
2020-06-23 |
2023-01-24 |
Hoffmann La Roche |
Moleculas agonistas de union al antigeno cd28 que se dirigen a her2.
|
|
EP4172203A1
(de)
|
2020-06-25 |
2023-05-03 |
F. Hoffmann-La Roche AG |
Anti-cd3/anti-cd28 bispezifische antigenbindende moleküle
|
|
EP4244254A1
(de)
|
2020-11-16 |
2023-09-20 |
F. Hoffmann-La Roche AG |
Kombinationstherapie mit fap-gerichteten cd40-agonisten
|
|
TW202241490A
(zh)
|
2020-12-18 |
2022-11-01 |
瑞典商阿斯特捷利康公司 |
用於治療氣喘之脂質運載蛋白突變蛋白乾粉配製物
|
|
MX2023007846A
(es)
|
2021-01-06 |
2023-07-07 |
Hoffmann La Roche |
Tratamiento conjunto que usa un anticuerpo biespecifico contra pd1-lag3 y un anticuerpo biespecifico de linfocitos t cd20.
|
|
KR20230152032A
(ko)
|
2021-02-03 |
2023-11-02 |
모차르트 쎄라퓨틱스 인코포레이티드 |
결합제 및 이를 사용하는 방법
|
|
WO2022184659A1
(en)
|
2021-03-01 |
2022-09-09 |
Quadrucept Bio Limited |
Antibody domains & multimers
|
|
CN117355319A
(zh)
|
2021-03-23 |
2024-01-05 |
皮里斯制药有限责任公司 |
用于癌症治疗的her2/4-1bb双特异性融合蛋白
|
|
CA3214220A1
(en)
|
2021-04-08 |
2022-10-13 |
Marina PAVLIDOU |
Novel lipocalin muteins specific for connective tissue growth factor (ctgf)
|
|
WO2022243341A1
(en)
|
2021-05-18 |
2022-11-24 |
Pieris Pharmaceuticals Gmbh |
Lipocalin muteins with binding affinity for ox40
|
|
WO2022243261A1
(en)
|
2021-05-19 |
2022-11-24 |
F. Hoffmann-La Roche Ag |
Agonistic cd40 antigen binding molecules targeting cea
|
|
AR126009A1
(es)
|
2021-06-02 |
2023-08-30 |
Hoffmann La Roche |
Moléculas agonistas de unión al antígeno cd28 que se dirigen a epcam
|
|
CA3223534A1
(en)
|
2021-07-02 |
2023-01-05 |
Genentech, Inc. |
Methods and compositions for treating cancer
|
|
WO2023076876A1
(en)
|
2021-10-26 |
2023-05-04 |
Mozart Therapeutics, Inc. |
Modulation of immune responses to viral vectors
|
|
TW202334203A
(zh)
|
2021-11-19 |
2023-09-01 |
德商皮里斯製藥有限公司 |
新穎的ox40及pd-l1特異性融合蛋白
|
|
CR20240246A
(es)
|
2021-12-20 |
2024-07-19 |
Hoffmann La Roche |
Anticuerpos agonistas anti-ltbr y anticuerpos biespecificos que los comprenden
|
|
WO2023186756A1
(en)
|
2022-03-28 |
2023-10-05 |
F. Hoffmann-La Roche Ag |
Interferon gamma variants and antigen binding molecules comprising these
|
|
WO2024030956A2
(en)
|
2022-08-03 |
2024-02-08 |
Mozart Therapeutics, Inc. |
Cd39-specific binding agents and methods of using the same
|
|
EP4587123A1
(de)
|
2022-09-15 |
2025-07-23 |
Avidicure IP B.V. |
Multispezifische antigenbindende proteine zur tumorgerichteten annk-zellen und verwendung davon
|
|
WO2024064713A1
(en)
|
2022-09-21 |
2024-03-28 |
Seagen Inc. |
Novel fusion protein specific for cd137 and cd228
|
|
GB202216503D0
(en)
|
2022-11-05 |
2022-12-21 |
Quadrucept Bio Ltd |
Non-human vertebrates & cells
|
|
JP2026510584A
(ja)
|
2023-03-13 |
2026-04-08 |
エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト |
Ｐｄ１－ｌａｇ３二重特異性抗体およびｈｌａ－ｇ ｔ細胞二重特異性抗体を用いる併用療法
|
|
CN121194993A
(zh)
|
2023-05-24 |
2025-12-23 |
莫扎特治疗公司 |
Cd8特异性结合蛋白及其应用方法
|
|
WO2024246083A1
(en)
|
2023-06-01 |
2024-12-05 |
F. Hoffmann-La Roche Ag |
Bispecific antibodies targeting bcma and cd28
|
|
WO2024246086A1
(en)
|
2023-06-01 |
2024-12-05 |
F. Hoffmann-La Roche Ag |
Immunostimulatory antigen binding molecules that specifically bind to bcma
|
|
AU2024311339A1
(en)
|
2023-06-21 |
2026-01-08 |
F. Hoffmann-La Roche Ag |
Combination therapy with fap-targeted lymphotoxin beta receptor agonists
|
|
AU2024290964A1
(en)
|
2023-07-05 |
2026-01-08 |
CSL Innovation Pty Ltd |
Methods of treating or preventing a complication of sickle cell disease
|
|
WO2025149633A1
(en)
|
2024-01-12 |
2025-07-17 |
Laigo Bio B.V. |
Bispecific antigen binding proteins
|
|
WO2025175123A1
(en)
|
2024-02-16 |
2025-08-21 |
Seagen Inc. |
Methods of treating cancer using fusion proteins specific for cd137 and cd228
|
|
WO2025191136A1
(en)
|
2024-03-15 |
2025-09-18 |
Avidicure Ip B.V. |
Muteins of 4-1bb ligand extracellular domain, fusion proteins comprising the same and uses thereof
|
|
WO2025191133A1
(en)
|
2024-03-15 |
2025-09-18 |
Avidicure Ip B.V. |
Il-21 muteins, fusion proteins comprising the same and uses thereof
|
|
WO2025191137A1
(en)
|
2024-03-15 |
2025-09-18 |
Avidicure Ip B.V. |
Conjugates of trop2-specific antigen binding proteins and cytokines
|
|
WO2025222129A2
(en)
|
2024-04-19 |
2025-10-23 |
Mozart Therapeutics, Inc. |
Engineered cytokines and targeted cytokine delivery
|
|
WO2026087748A1
(en)
|
2024-10-24 |
2026-04-30 |
Avidicure Ip B.V. |
Multispecific antigen binding proteins for the expansion of γδ t cells and use thereof
|
|
WO2026087747A1
(en)
|
2024-10-24 |
2026-04-30 |
Avidicure Ip B.V. |
Multispecific antigen binding proteins for tumor-targeting of γδ1 t cells and use thereof
|
|
WO2026093923A1
(en)
|
2024-10-29 |
2026-05-07 |
Csl Behring Ag |
Method for detection of a plasma protein
|